652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I

Impact AL A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

National trends and disparities in AL amyloidosis related mortality among multiple myeloma patients in the United States A population based study 1999–2023

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab based therapies

Characteristics and clinical course of younger Patients  with early lesions in a contemporary cohort of 1240 patients Low risk features and low risk of complications

Prognostic analysis of newly diagnosed systemic light chain amyloidosis patients treated with daratumumab

Proteomic profiling of amyloid deposits in advanced systemic light chain AL amyloidosis Insights into clonal light chains chaperone proteins and cardiac involvement

Daratumumab pomalidomide dexamethasone DPd in newly diagnosed AL amyloidosis High rates of hematologic and organ responses with manageable safety

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS

Management and long term hematologic and neurologic outcomes of IgM related neuropathy A single center experience

Diagnostic and prognostic value of 18f florbetapir PET CT in systemic light chain amyloidosis

The real world safety and efficacy of bispecific t cell engager therapy in systemic AL amyloidosis

The real world safety and efficacy of BCMA directed chimeric antigen receptor T cell therapy in systemic AL amyloidosis

External validation of the istopmm prediction model in a US population